Inventor · disambiguated record
Mahendra G. Dedhiya
Also filed as: DEDHIYA MAHENDRA · DEDHIYA MAHENDRA G
26 granted patents·70 pending applications·239 citations·filing 2000–2024
96Inventor score
Files withFOREST LAB HOLDINGS LTD32IRONWOOD PHARMACEUTICALS INC18FOREST LABORATORIES9DEDHIYA MAHENDRA G7FOREST LABORATORIES HOLDINGS LTD6
Top patents by PatentIndex Score
96 records- 0194US9062053B2Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-Diazabicyclo[3,2,1]octane-2-carboxamide sodium saltFOREST LAB HOLDINGS LTD·Filed 2014·Granted Jun 23, 2015·15 cites·9 claims
- 0294US8835455B2Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium saltFOREST LAB HOLDINGS LTD·Filed 2013·Granted Sep 16, 2014·15 cites·10 claims
- 0393US8471025B2Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium saltDEDHIYA MAHENDRA G·Filed 2010·Granted Jun 25, 2013·26 cites·34 claims
- 0492US8039009B2Modified release formulations of memantine oral dosage formsFOREST LAB HOLDINGS LTD·Filed 2005·Granted Oct 18, 2011·61 cites·23 claims
- 0591USRE47350EPharmaceutical formulations containing dopamine receptor ligandsRICHTER GEDEON NYRT·Filed 2017·Granted Apr 16, 2019·4 cites·10 claims
- 0691USRE47333EPharmaceutical formulations containing dopamine receptor ligandsRICHTER GEDEON NYRT·Filed 2017·Granted Apr 2, 2019·4 cites·10 claims
- 0791US9284314B2Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereofRONSHEIM MELANIE SIMONE·Filed 2015·Granted Mar 15, 2016·15 cites·15 claims
- 0891US8829191B2Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereofRONSHEIM MELANIE SIMONE·Filed 2012·Granted Sep 9, 2014·18 cites·7 claims
- 0990US8969566B2Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereofRONSHEIM MELANIE SIMONE·Filed 2014·Granted Mar 3, 2015·17 cites·9 claims
- 1090US8748573B2Formulations comprising linaclotideFRETZEN ANGELIKA·Filed 2010·Granted Jun 10, 2014·8 cites·10 claims
- 1188US9056846B2Pharmaceutical formulations containing dopamine receptor ligandsRICHTER GEDEON NYRT·Filed 2012·Granted Jun 16, 2015·4 cites·10 claims
- 1286US8802628B2Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administrationFRETZEN ANGELIKA·Filed 2009·Granted Aug 12, 2014·7 cites·26 claims
- 1385USRE49110EPharmaceutical formulations containing dopamine receptor ligandsRICHTER GEDEON NYRT·Filed 2019·Granted Jun 21, 2022·1 cites·11 claims
- 1485US2023346881A1Stable Formulations of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1584US6747058B1Stable composition for inhalation therapy comprising delta-9-tetrahydrocannabinol and semiaqueous solvent thereforUNIMED PHARMACEUTICALS INC·Filed 2000·Granted Jun 8, 2004·36 cites·20 claims
- 1683US9056845B2Pharmaceutical formulations containing dopamine receptor ligandsSARKAR RANAJOY·Filed 2009·Granted Jun 16, 2015·4 cites·10 claims
- 1783US2023310329A1Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1879US2025073301A1Delayed Release Compositions of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1979US2022233635A1Stable Formulations of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2078US10675325B2Stable formulations of linaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2019·Granted Jun 9, 2020·0 cites·18 claims
- 2178US2022125734A1Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2275US10702576B2Stable formulations of linaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2019·Granted Jul 7, 2020·0 cites·20 claims
- 2375US2021290554A1Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2475US2023398173A1Delayed Release Compositions of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2574USRE49302EPharmaceutical formulations containing dopamine receptor ligandsRICHTER GEDEON NYRT·Filed 2019·Granted Nov 15, 2022·0 cites·15 claims
- 2673US2023142270A1Delayed Release Compositions of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2770US2014287034A1Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2869US2009247644A1Memantine formulationsFOREST LAB HOLDINGS LTD·Filed 2009·Application pending·0 cites
- 2968US9259403B2Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamideFOREST LAB HOLDINGS LTD·Filed 2014·Granted Feb 16, 2016·0 cites·6 claims
- 3068US2020009216A1Stable Formulations of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3167US2020268685A1Modified release formulations of memantine oral dosage formsFOREST LABORATORIES HOLDINGS LTD·Filed 2020·Application pending·0 cites
- 3266US7648696B2Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solventUNIMED PHARMACEUTICALS LLC·Filed 2003·Granted Jan 19, 2010·4 cites·10 claims
- 3365US2013302430A1Modified and immediate release formulations of memantineFOREST LAB HOLDINGS LTD·Filed 2013·Application pending·0 cites
- 3465US2019029967A1Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 3564US2014378393A1Stable Formulations of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3664US2010035995A1Compositions comprising Cyclohexylamines and AminoadamantanesMERZ PHARMA GMBH & CO KGAA·Filed 2009·Application pending·0 cites
- 3763US10660868B2Modified release formulations of memantine oral dosage formsFOREST LABORATORIES HOLDINGS LTD·Filed 2016·Granted May 26, 2020·0 cites·8 claims
- 3863US2010028427A1Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexaneFOREST LABORATORIES·Filed 2009·Application pending·0 cites
- 3963US2016310559A1Delayed Release Compositions of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 4063US2017210742A1Novel crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium saltFOREST LABORATORIES HOLDINGS LTD·Filed 2017·Application pending·0 cites
- 4162US2013210919A1Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamideFOREST LAB HOLDINGS LTD·Filed 2013·Application pending·0 cites
- 4261US9580424B2Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium saltFOREST LABORATORIES HOLDINGS LTD·Filed 2015·Granted Feb 28, 2017·0 cites·54 claims
- 4361US2014213659A1Modified release formulations of memantine oral dosage formsFOREST LAB HOLDINGS LTD·Filed 2014·Application pending·0 cites
- 4461US2009082326A1Soluble dosage forms containing cephem derivatives suitable for parenteral administrationFOREST LAB HOLDINGS LTD·Filed 2008·Application pending·0 cites
- 4561US2013273169A1Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationFOREST LAB HOLDINGS LTD·Filed 2013·Application pending·0 cites
- 4661US2015065582A1Orally Dissolving Formulations of MemantineFOREST LAB HOLDINGS LTD·Filed 2014·Application pending·0 cites
- 4760US2013190239A1Formulations Comprising LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 4860US2012201889A1Modified and immediate release formulations of memantineDEDHIYA MAHENDRA G·Filed 2012·Application pending·0 cites
- 4960US2015132375A1Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 5060US2013310460A1Modified release formulations of memantine oral dosage formsFOREST LAB HOLDINGS LTD·Filed 2013·Application pending·0 cites
Showing the top 50 of 96 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →